Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment Journal of Medicinal Chemistry CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 Hypertension Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants Gabe 2024 Diabetes, Obesity and Metabolism Wiley Online Library